Novo Nordisk Teams With WeightWatchers to Expand Wegovy Access

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on June 26 that it will collaborate with WeightWatchers to begin distributing the bestselling weight-loss medication Wegovy, beginning July 1.

The agreement allows cash-paying patients to purchase a month’s supply of Wegovy for $299 at the Danish pharmaceutical company’s Novocare pharmacy. Novo’s other telehealth partners will also be able to provide the one-time fee through July 31.

Novo Nordisk Teams With WeightWatchers to Expand Wegovy Access

Pixabay/Public Domain

Compounded forms of semaglutide, the active component of Wegovy and other Novo Nordisk A/S (NYSE:NVO) medications, are no longer available from WeightWatchers, which has emerged from bankruptcy. According to Evan Seigerman, an analyst at BMO Capital Markets, the collaboration enables WeightWatchers to revive its weight-loss medication approach while also assisting Novo Nordisk A/S (NYSE:NVO) in gaining patients who have been using compounded forms of the medication.

Novo Nordisk A/S (NYSE:NVO) is a prominent global healthcare company that focuses on treating rare diseases, diabetes, and obesity. With 48,000 workers spread across more than 168 countries, Novo Nordisk is well-known for its pharmaceuticals, which include Wegovy, Rybelsus, and Ozempic.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.